{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:24:22Z","timestamp":1790504662425,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T00:00:00Z","timestamp":1515369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.clcc.2017.12.004","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T08:53:54Z","timestamp":1513155234000},"page":"85-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review"],"prefix":"10.1016","volume":"17","author":[{"given":"Mario E.","family":"Lacouture","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Anadkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aminah","family":"Jatoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Garawin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chet","family":"Bohac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2017.12.004_bib1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ijc.28722","article-title":"Molecular therapy of colorectal cancer: progress and future directions","volume":"136","author":"Weng","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib2","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib4","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2017.12.004_bib5","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib6","series-title":"Erbitux (cetuximab). Summary of product characteristics","year":"2014"},{"key":"10.1016\/j.clcc.2017.12.004_bib7","series-title":"Erbitux\u00ae, cetuximab","year":"2015"},{"key":"10.1016\/j.clcc.2017.12.004_bib8","series-title":"Vectibix (panitumumab). Summary of product characteristics","year":"2013"},{"key":"10.1016\/j.clcc.2017.12.004_bib9","series-title":"Vectibix\u00ae, panitumumab","year":"2015"},{"key":"10.1016\/j.clcc.2017.12.004_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00384-014-2097-2","article-title":"Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer","volume":"30","author":"Jin","year":"2015","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.clcc.2017.12.004_bib11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bjc.2015.480","article-title":"Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer","volume":"114","author":"Elez","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ejca.2013.10.015","article-title":"Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma","volume":"50","author":"Delord","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib13","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/annonc\/mdt523","article-title":"Final results from a randomized phase 3 study of FOLFIRI {+\/-} panitumumab for second-line treatment of metastatic colorectal cancer","volume":"25","author":"Peeters","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib15","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib16","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib17","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2017.12.004_bib18","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2015.05.017","article-title":"Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials","volume":"51","author":"Peeters","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib19","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ejca.2015.04.007","article-title":"FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"51","author":"Bokemeyer","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Van Cutsem","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib21","series-title":"NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers, v2.2014","year":"2014"},{"issue":"suppl 3","key":"10.1016\/j.clcc.2017.12.004_bib22","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib23","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2017.12.004_bib24","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1634\/theoncologist.2008-0149","article-title":"Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy","volume":"13","author":"Jatoi","year":"2008","journal-title":"Oncologist"},{"issue":"suppl 1","key":"10.1016\/j.clcc.2017.12.004_bib25","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.6004\/jnccn.2009.0074","article-title":"NCCN task force report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer","volume":"7","author":"Burtness","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clcc.2017.12.004_bib26","series-title":"Erbitux European Public Assessment Report, Summary of Product Characteristics","year":"2015"},{"key":"10.1016\/j.clcc.2017.12.004_bib27","series-title":"Vectibix European Public Assessment Report, Summary of Product Characteristics","year":"2016"},{"key":"10.1016\/j.clcc.2017.12.004_bib28","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/fon.14.251","article-title":"Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP","volume":"11","author":"Kobayashi","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib30","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11523-013-0257-x","article-title":"The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials","volume":"8","author":"Petrelli","year":"2013","journal-title":"Target Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib32","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","article-title":"Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic","volume":"14","author":"Rosen","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clcc.2017.12.004_bib34","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.clcc.2017.12.004_bib35","first-page":"247","article-title":"Meta-analysis: the efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer","volume":"10","author":"Nie","year":"2009","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.clcc.2017.12.004_bib36","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","article-title":"Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study","volume":"15","author":"Price","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib37","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1200\/jco.2010.28.15_suppl.3528","article-title":"Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): efficacy by skin toxicity (ST) [abstract]","volume":"28","author":"Douillard","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib38","series-title":"Common Terminology Criteria for Adverse Events (CTCAE), version 4.0","year":"2010"},{"key":"10.1016\/j.clcc.2017.12.004_bib39","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/annonc\/mdq387","article-title":"Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion","volume":"22","author":"Potthoff","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1468-3083.2009.03446.x","article-title":"Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer","volume":"24","author":"Ocvirk","year":"2010","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clcc.2017.12.004_bib41","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","article-title":"A\u00a0randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer","volume":"27","author":"Hecht","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib42","first-page":"72","article-title":"SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer","volume":"14","author":"Hecht","year":"2015","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib43","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib44","first-page":"333","article-title":"The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (skin toxicity evaluation protocol with panitumumab) by KRAS status","volume":"10","author":"Mitchell","year":"2011","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib45","first-page":"1167","article-title":"Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review","volume":"21","author":"Borkar","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/era.10.28","article-title":"Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer","volume":"10","author":"Addeo","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clcc.2017.12.004_bib47","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s10103-011-1029-4","article-title":"Acneiform rash due to epidermal growth factor receptor inhibitors: high-level laser therapy as an innovative approach","volume":"27","author":"Gobbo","year":"2012","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.clcc.2017.12.004_bib48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3747\/co.v16i1.361","article-title":"Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations","volume":"16","author":"Melosky","year":"2009","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","article-title":"Skin toxicities associated with epidermal growth factor receptor inhibitors","volume":"4","author":"Li","year":"2009","journal-title":"Target Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejon.2010.03.004","article-title":"Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer","volume":"14","author":"Ouwerkerk","year":"2010","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.clcc.2017.12.004_bib51","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1634\/theoncologist.2010-0298","article-title":"Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy","volume":"16","author":"Pinto","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2017.12.004_bib52","series-title":"\u201cAlcohol Free.\u201d","year":"2014"},{"key":"10.1016\/j.clcc.2017.12.004_bib53","first-page":"799","article-title":"Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer","volume":"24","author":"Dascalu","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/OTT.S31412","article-title":"Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer","volume":"5","author":"Fuloria","year":"2012","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clcc.2017.12.004_bib55","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jaad.2014.06.011","article-title":"Managing skin toxicities related to panitumumab","volume":"71","author":"Bergman","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.clcc.2017.12.004_bib56","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3747\/co.v17is1.615","article-title":"Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer","volume":"17","author":"Fakih","year":"2010","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib57","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1684\/ejd.2009.0650","article-title":"Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients","volume":"19","author":"de Noronha e Menezes","year":"2009","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clcc.2017.12.004_bib58","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ad.2015.01.006","article-title":"Predictors of tumor response to cetuximab and panitumumab in 116 patients and a review of approaches to managing skin toxicity","volume":"106","author":"Jaka","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.clcc.2017.12.004_bib59","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/COC.0000000000000291","article-title":"Management of skin reactions during cetuximab treatment in association with chemotherapy or radiotherapy: update of the Italian expert recommendations","volume":"39","author":"Pinto","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib60","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nrclinonc.2009.16","article-title":"Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer","volume":"6","author":"Eng","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib62","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s12094-010-0551-3","article-title":"Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome","volume":"12","author":"Garcia-Foncillas","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib63","doi-asserted-by":"crossref","first-page":"434","DOI":"10.7547\/87507315-89-8-434","article-title":"Superglue for the treatment of heel fissures","volume":"89","author":"Hashimoto","year":"1999","journal-title":"J\u00a0Am Podiatr Med Assoc"},{"key":"10.1016\/j.clcc.2017.12.004_bib64","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ejca.2006.11.016","article-title":"Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors","volume":"43","author":"Galimont-Collen","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib65","first-page":"1113","article-title":"Acute and chronic paronychia","volume":"63","author":"Rockwell","year":"2001","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clcc.2017.12.004_bib66","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5070\/D31M58Z039","article-title":"Unique presentations of epidermal growth factor receptor inhibitor-induced papulopustular eruption related to bacterial superinfection","volume":"19","author":"Wiznia","year":"2013","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.clcc.2017.12.004_bib67","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/01.NCC.0000281759.23823.82","article-title":"Ocular toxicities of epidermal growth factor receptor inhibitors and their management","volume":"30","author":"Basti","year":"2007","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.clcc.2017.12.004_bib68","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7819-12-35","article-title":"A\u00a0case report on efficacy of Abound for anti-EGFR antibody-associated skin disorder in metastatic colon cancer","volume":"12","author":"Matsuhashi","year":"2014","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib69","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clnu.2005.01.006","article-title":"Dietary treatment of rheumatoid cachexia with beta-hydroxy-beta-methylbutyrate, glutamine and arginine: a randomised controlled trial","volume":"24","author":"Marcora","year":"2005","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clcc.2017.12.004_bib70","first-page":"1179","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of a \u03b2-hydroxyl \u03b2-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122)","volume":"16","author":"Berk","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib71","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1468-3083.2011.04324.x","article-title":"Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis","volume":"27","author":"Tomkova","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clcc.2017.12.004_bib72","first-page":"62","article-title":"Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer","volume":"13","author":"Pinta","year":"2014","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib73","first-page":"1499","article-title":"Drug-induced skin toxicity and clinical nursing of VitK cream on colorectal cancer patients","volume":"28","author":"Li","year":"2015","journal-title":"Pak J Pharm Sci"},{"key":"10.1016\/j.clcc.2017.12.004_bib74","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s10637-014-0128-z","article-title":"The efficacy of Pistacia terebinthus soap in the treatment of cetuximab-induced skin toxicity","volume":"32","author":"Tastekin","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clcc.2017.12.004_bib75","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2017.12.004_bib76","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/cncr.24088","article-title":"Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy","volume":"115","author":"Peeters","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib77","first-page":"351210","article-title":"Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: pathophysiology and management","volume":"2012","author":"Abdullah","year":"2012","journal-title":"Chemother Res Pract"},{"issue":"suppl 1","key":"10.1016\/j.clcc.2017.12.004_bib78","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0305-7372(10)00036-8","article-title":"The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer","volume":"36","author":"Bouche","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clcc.2017.12.004_bib79","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1634\/theoncologist.2011-0163","article-title":"Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs","volume":"16","author":"Dienstmann","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2017.12.004_bib80","first-page":"849051","article-title":"Clinical significance of skin toxicity due to EGFR-targeted therapies","volume":"2009","author":"Giovannini","year":"2009","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib81","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3748\/wjg.v22.i2.887","article-title":"Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer","volume":"22","author":"Kubo","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clcc.2017.12.004_bib82","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-014-0322-0","article-title":"Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer","volume":"10","author":"Kogawa","year":"2015","journal-title":"Target Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib83","doi-asserted-by":"crossref","first-page":"e15980","DOI":"10.1371\/journal.pone.0015980","article-title":"Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >\/= 2 line cetuximab-based therapy of colorectal cancer patients","volume":"6","author":"Saridaki","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2017.12.004_bib84","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/jjco\/hyu008","article-title":"A\u00a0prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial","volume":"44","author":"Ooki","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib85","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3109\/0284186X.2013.879202","article-title":"The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG\/AGITG CO.17","volume":"53","author":"Sommeijer","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clcc.2017.12.004_bib86","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/1471-2407-12-438","article-title":"Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study","volume":"12","author":"Thaler","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib87","first-page":"329","article-title":"Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients","volume":"18","author":"Romito","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib88","first-page":"733","article-title":"Treatment of metastatic colorectal cancer with cetuximab: influence on the quality of life","volume":"51","author":"Unger","year":"2013","journal-title":"Z\u00a0Gastroenterol"},{"key":"10.1016\/j.clcc.2017.12.004_bib89","first-page":"1691","article-title":"Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline: a phase II study","volume":"21","author":"Grande","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clcc.2017.12.004_bib90","first-page":"371","article-title":"Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies","volume":"15","author":"Burudpakdee","year":"2012","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clcc.2017.12.004_bib91","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/030089161209800402","article-title":"The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospective economic assessment from a single-center experience","volume":"98","author":"Giuliani","year":"2012","journal-title":"Tumori"},{"key":"10.1016\/j.clcc.2017.12.004_bib92","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy","volume":"102","author":"Eilers","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300281630278X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300281630278X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:07:06Z","timestamp":1761520026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153300281630278X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S153300281630278X"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2017.12.004","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2017.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}